The Governance Board is the governing body of the Medicines Patent Pool, with the highest authority for making decisions according to its statutes [pdf]. Among its key duties, it sets policies and strategies for the MPP, oversees its work plan and financial matters, and monitors and evaluates the MPP’s performance. It also appoints the Executive Director and Governance Board members. The MPP’s Executive Director attends Governance Board meetings without a right to vote.
Charles Clift, Bernard Pécoul, and Paulo Teixeira were the initial voting members of the Governance Board. In September 2011, Sigrun Møgedal and Precious Matsoso joined the Board; in October 2012, Anna Zakowicz also joined the board. In October 2012, Precious Matsoso resigned from the board and was replaced by Anban Pillay. In October 2015 Claudia Chamas, Michel Manon, Brian Tempest and Jayashree Watal were appointed.
Members of the Board serve in their personal capacities. The Governance Board may include up to nine voting members, plus three non-voting participants in total, one of whom is the chair of the Expert Advisory Group.
In line with the MPP’s transparency policy the Governance decisions are published on the foundation’s website.
Governance Board members include:
Dr Sigrun Møgedal is a medical doctor, former Ambassador for HIV/AIDS and Global Health Initiatives for Norway, and former Chair of the Board for the Global Health Workforce Alliance at the World Health Organization. She was previously senior advisor to the Norwegian Agency for Development Cooperation (NORAD), and senior policy adviser to the Executive Director of UNAIDS. She serves on the boards of the Global Fund to Fight AIDS, TB, and Malaria, the Global Alliance for Vaccines and Immunisation (GAVI), and UNITAID, and was a founding member of the board at the Global Forum for Health Research. She is currently a special adviser to the Executive Director of UNAIDS and serves as a member of the Independent Monitoring Board for Polio Eradication. She was awarded the status of Knight First Class in the Royal Norwegian Order of Saint Olav and was appointed an officer of the National Order of Merit of France.
Dr. Claudia Chamas has dedicated her career to studying the impact of intellectual property rights on access to medicines. She is a researcher at the Centre for Technological Development in Health (CDTS) of the Oswaldo Cruz Foundation (Fiocruz). In collaboration with Fiocruz, she played an active role in the creation of the Master and Doctoral Programmes in Public Policies, Strategy and Development at the Institute of Economics, Federal University of Rio de Janeiro where she teaches and supervises dissertations. Dr. Chamas was the representative of the Ministry of Health at the Brazilian Interministerial Group on Intellectual Property and vice-chair of the WHO Expert Consultative Working Group on Research and Development (CEWG). She is the author of articles and book chapters in the fields of international intellectual property policies, health innovation and technology transfer. She holds a bachelor degree in Chemical Engineering and a doctoral degree in Industrial Engineering from the Federal University of Rio de Janeiro.
Trained as an economist at Cambridge and Sussex Universities, Charles Clift undertook a wide range of roles during his career as an economist with the UK Department for International Development (DFID). He lived and worked in Kenya, India, the Caribbean and Geneva. From 2001 to 2002, he acted as Head of the Secretariat of the U.K. Commission on Intellectual Property Rights. From 2004 to 2006, he was employed in a similar capacity by the World Health Organization (WHO) Commission on Intellectual Property Rights, Innovation and Public Health which recommended that further work be done to evaluate the feasibility of patent pools to promote innovation and improve access. He was also the principal consultant in drafting the report of the WHO’s Consultative Expert Working Group on Research and Development: Financing and Coordination. In recent years, Dr Clift has worked extensively with other donors, the pharmaceutical industry (both brand-name and generic), governments and civil society on ways to improve access to medicines in developing countries, including through the use of innovative intellectual property mechanisms.
Dr. Michel Manon comes to MPP with a long tenure in the pharmaceutical industry. A medical doctor by training, he spent several years of service in emergency and intensive medicine before joining the industry as Medical Director of Bristol-Myers Squibb (then Bristol Myers) in 1980. Dr. Manon spent more than 30 years at BMS in several senior positions, including Marketing and Medical Director Africa and most recently Vice-President Non-Communicable Diseases Strategy. Dr. Manon has played an active role in establishing BMS’s access to medicines agenda in Africa, and has worked in challenging posts throughout the continent as well as in Asia and Europe. In 2011, he led a task-force for a research study in Russia “Population Attitude to Personal Health: Perception of Health, Understanding of Risk-Factors, Morbidity and Mortality,” which was presented to the WHO Global Forum.
Dr Bernard Pécoul has led the Drugs for Neglected Diseases initiative (DNDi) since its foundation in 2003. Under his guidance, DNDi – a not-for-profit research and development organization – with hundreds of public and private partners, has delivered six new treatments for the most neglected diseases (leishmaniasis, sleeping sickness, and Chagas disease) and for malaria. It has developed a robust portfolio of projects spanning from discovery to implementation for these diseases as well as filaria, paediatric HIV, mycetoma, and hepatits C. The initiative, through a dynamic portfolio approach to R&D, aims to deliver a total of 16 to 18 new treatments for neglected patients by 2023, with a total of EUR 650 million, covering a span of 10 disease areas. Through its work, DNDi also builds capacity in disease endemic countries through research platforms and technology transfers and advocates for greater public leadership to sustainably address the health needs of neglected patients.
Prior to DNDi, Dr Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of Executive Director of MSF-France. While working with MSF, Dr Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specialized in epidemiology.
After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws Degree by the University of Dundee, UK.
Anban Pillay is a South African national who currently holds the position of Deputy Director General for Health Regulation and Compliance with the country’s National Department of Health. He is also a member of the Council for Medical Schemes, sits on the Global Fund Expert Advisory Committee and the UNICEF/GAVI Expert Advisory Committee. He is an Honorary Senior Lecturer at the University of KwaZulu Natal. Dr. Pillay’s research focuses on: drug utilisation; knowledge, attitude and behaviour of prescribers; drug selection by pharmacy and therapeutics committees; meta-analyses and systematic reviews; and cost effective analyses. He earned his PhD from the University of Newcastle, Australia and also holds a Masters of Clinical Pharmacology from the Nelson Mandela School of Medicine and a Bachelors of Pharmacy from the University of KwaZulu Natal.
Dr. Brian Tempest is currently an international advisor to the United Nations Conference on Trade and Development (UNCTD) and MAPE, India. He has worked in the pharmaceutical industry for the last 45 years and has managed healthcare businesses in the Americas, Europe, Africa and Asia. Dr. Tempest joined Ranbaxy Laboratories in 1995, serving in several senior positions, including Managing Director and Chief Executive Officer, until his retirement in 2008. He also was Regional Director-Far East and Regional Director-Middle East and Africa for GlaxoSmithKilne. Dr. Tempest received a PhD in Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School. He is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Medicine and has non-executive status in several India companies such as Glenmark Pharmaceuticals and Fortis Healthcare.
Ms. Jayashree Watal has been Counsellor in the Intellectual Property Division of the World Trade Organization since February 2001. She also holds the part-time position of Adjunct Professor of Law at the Georgetown University Law Center and teaches intellectual property law and economics for the University of Barcelona’s IELPO programme. Ms. Watal holds postgraduate degrees in both law and economics and has more than twenty-two years of experience in government in India. She has researched and published articles on issues related to the law and economics of intellectual property rights, including a book “Intellectual Property Rights in the WTO and Developing Countries” (Oxford University Press, India and Kluwer Law International, 2001). She was also a Visiting Scholar at the Center for International Development at Harvard University, at the Peterson Institute for International Economics, and at George Washington University Law School.
Ms Anna Zakowicz is the co-chair of the Board of Directors at the Global Network of People Living with HIV (GNP+), a member of the Board of Directors of European AIDS Treatment Group (EATG) and the co-chair of the Civil Society Forum on HIV/AIDS at the European Commission. Ms Zakowicz has been active in communities of people living with HIV, people who use drugs and women affected by HIV for years, holding leadership roles at both GNP+ and EATG, and as an independent expert. She brings extensive experience on treatment access issues facing Eastern Europe and Central Asia to her new role. Among her achievements to-date, Ms Zakowicz developed an assessment tool to determine national-level gaps in HIV, Hepatitis C and Tuberculosis care; acted as a community expert on HIV/AIDS treatment in Latvia; and worked as a focal point in Eastern Europe and Central Asia to increase meaningful participation of women at the UN High Level Meeting on AIDS. She has developed and run trainings in HIV treatment literacy and advocacy, management of healthcare and programmes for people who use drugs in Lithuania, Estonia, Ukraine, Kazakhstan, Kyrgyzstan, Tajikistan, Austria and Belgium.